tbuckley/cabot-search huggingface dataset:
Hyper-CVAD Program in Burkitt's-Type Adult Acute Lymphoblastic Leukemia
Authors: Deborah A. Thomas, Jorge Cortes, Susan O'Brien, Sherry Pierce, Stefan Faderl, Maher Albitar, Frederick B. Hagemeister, Fernando F. Cabanillas, Sharon Murphy, Michael J. Keating, Hagop Kantarjian
Journal: Journal of Clinical Oncology (1999)

PURPOSE: To evaluate response and outcome with a front-line intensive multiagent chemotherapy regimen in adults with Burkitt's-type acute lymphoblastic leukemia (B-ALL). PATIENTS AND METHODS: From September 1992 to June 1997, 26 consecutive adults with newly diagnosed untreated B-ALL received hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD). Their median age was 58 years (range, 17 to 79 years), and 46% were ≥ 60 years. Patients received Hyper-CVAD alternated with courses of high-dose methotrexate and cytarabine. Granulocyte colony-stimulating factor and prophylactic antibiotics were administered for all eight planned courses. CNS prophylaxis alternated intrathecal methotrexate and cytarabine on days 2 and 7 of each course. RESULTS: Complete remission (CR) was obtained in 21 patients (81%). There were five induction deaths (19%). The median time to CR was 22 days (range, 15 to 89 days); 70% achieved CR within 4 weeks. The 3-year survival rate was 49% (± 11%); the 3-year continuous CR rate was 61% (± 11%). Twelve CR patients (57%) were in continuous CR at a median follow-up of 3+ years (range, 13+ months to 6.5+ years). Characteristics predicting for worse survival were age ≥ 60 years, poor performance status, anemia, thrombocytopenia, peripheral blasts, and increased lactate dehydrogenase level. The 3-year survival rate was 77% for 14 patients younger than 60 years and 17% for 12 patients ≥ 60 years (P &lt; .01). Regression analysis identified older age, anemia, and presence of peripheral blasts as independent factors associated with shorter survival. Patients could be stratified according to (1) no or one adverse feature, (2) two adverse features, and (3) all adverse features. The 3-year survival rates were 89%, 47%, and 0%, respectively (P &lt; .01). CONCLUSION: Hyper-CVAD is effective in adult B-ALL. Identification of patients with high risk for relapse and improved methods to detect residual disease may result in risk-oriented approaches.
Assessment of relationship between snoring and ischemic heart disease
Authors: Abolfazl Mozafari, Zahra Afrakhteh, Fazeleh Shakeri
Journal: European Respiratory Journal (2013)

INTRODUCTION:  Snoring is common in the general population, with up to 25% of women and 45% of men reporting habitual snoring. Snoring is the main symptom of OSA, one of the  Most frequent symptom of OSA which affects 4% of middle-aged men and 2% of middle-aged women. Snoring were the associated with a significantly increased risk for acute myocardial infarction and stroke in men and women in some articles. Epidemiologic studies in Caucasian populations have shown association snoring and sleep apnea with vascular disease.  METHOD: This article was case-control study. All patients who were done coronary vessel angiography put in two groups. 93 patients were normal or  50% stenosis). Then complete demographic and laboratory data, ESS, Berlin questionnaire (risk factor for OSA) and analyze them in according to chi-square and pearson correlation coefficient in SPSS software 18.  RESULTS: mean age 56.8±12 that 119(59%) patients were female. There weren’t significant difference among snoring with IHD (76.7% and 62.8% in case and control respectively p=0.506), severe snoring with IHD (P=0.73) and snoring with ejection fraction (p=0.511). It was showed significant correlation among IHD with risk factor for OSA (p  CONCLUSION: in this study we showed that there wasn’t significant difference between snoring and severity of snoring with IHD.
Abnormal growth patterns and adult short stature in 115 long-term survivors of childhood leukemia.
Authors: E A Schriock, M J Schell, M Carter, O Hustu, J J Ochs
Journal: Journal of Clinical Oncology (1991)

Significant growth retardation was found in 115 survivors of childhood acute lymphoblastic leukemia (ALL) who had completed their growth. These children were diagnosed before 12 years of age and treated on four protocols in a single institution; all received either cranial (n = 78) or craniospinal (n = 37) prophylactic irradiation. Patients' heights at diagnosis were within expected ranges, but final heights were greater than or equal to 1 SD below population means in 74% of cases and greater than or equal to 2 SD in 37%. Effects on growth were more pronounced for children who had received craniospinal irradiation, but decrements were also significant in the cranial irradiation group, with adult heights greater than or equal to 2 SD below population norms in 32%. Growth retardation was significantly greater (P less than .0001) in children who had earlier disease onset. Growth deceleration occurred not only during chemotherapy but during a later period that followed an interval of improved growth in many cases. Thus, late decrements in growth may be missed in studies that do not follow patients until they have attained final heights. These findings indicate that abnormally short stature among survivors of ALL merits further clinical and research attention.
No strong association is found between pioglitazone and bladder cancer:
Authors: Jacqui Wise
Journal: BMJ (2015)

The diabetes drug pioglitazone is not associated with a statistically significant increased risk of bladder cancer, although a small increased risk cannot be excluded, new research published in JAMA has found.1

The researchers also found that the use of pioglitazone was associated with a higher risk of prostate and pancreatic cancer, although they said that further investigation is needed to assess whether the associations are causal or due to other factors.

The safety of pioglitazone, an oral antidiabetic agent in the thiazolidinedione class, is controversial. Preclinical studies of the drug in the 1990s showed an increase in bladder cancer in male rats, and early clinical …
Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer.
Authors: R P McQuellon, H B Muss, S L Hoffman, G Russell, B Craven, S B Yellen
Journal: Journal of Clinical Oncology (1995)

The purpose of this study was to elicit preferences for the treatment of metastatic breast cancer in women with early-stage breast cancer who were given hypothetical treatment scenarios. We predicted that quality of life, demographic, and treatment variables would have an impact on patient preferences.One hundred fifteen patients with stage 1-IIIA breast cancer were interviewed. All patients had either mastectomy or lumpectomy plus radiotherapy as primary treatment. Sixty-seven (58%) had prior adjuvant chemotherapy. Patients were given four clinical scenarios that described a woman with metastatic breast cancer who was stated to have a life expectancy of 18 months. Side effects of the treatment options were systematically varied from low (hormonal therapy) to life-threatening (high-dose experimental therapy) and were consistent with common clinical situations. Patients were asked to select which treatment, with its associated toxicity, they would accept and prefer for a 50% chance of specified increments in life expectancy, ie, 5 years, 18 months, 1 year, 6 months, 1 month, and 1 week.Quality of life at the time of interview, previous chemotherapy treatment, and degree of difficulty of previous treatments did not predict patient preferences. The greater the toxicity potential of the treatment, the less likely patients were to accept the treatment, although approximately 15% of patients would prefer high-risk treatment for as little as 1 month of added life expectancy. Between 34% and 82% of patients would prefer different therapies for a 6-month addition to life expectancy, whereas almost all patients would accept treatment for a 5-year increase in length of survival. Younger patients were more willing to assume the risks of treatment for a small increase in life expectancy. Of note, between 54% and 78% of patients would elect to start the different treatments even without symptoms related to metastatic disease. Moreover, 76% of patients would prefer standard treatment or an experimental agent to reduce symptoms or pain, even if such treatment did not prolong life. Additionally, only 10% of patients would allow randomization to a clinical trial comparing high-dose with standard chemotherapy. Participation in the study was not distressing to most patients.Patients showed clear preferences for specific treatments for metastatic disease when given hypothetical scenarios. There was a wide range of patient preferences for treatment based on risk-benefit assessment, but a substantial percentage of patients would accept the risk of major toxicity for minimal increase in overall survival.
Some NHS personal health budgets are spent on holidays and hobbies
Authors: Gareth Iacobucci
Journal: BMJ (2015)

NHS personal health budgets have been used to buy things such as holidays, horse riding lessons, and video game consoles, a freedom of information request has found.

The details were published by the general practitioners’ magazine Pulse after a request to clinical commissioning groups (CCGs) in England.1 Other examples of services purchased to date included art classes, music lessons, massages, and a summer house.

Personal health budgets were first piloted in the NHS in 20092 and were subsequently rolled out across England in 2014 to offer patients …
Challenge already established: Identification of risk factors for early need for ventilatory support in Duchenne muscular dystrophy
Authors: Leonardo Augusto Tavares, Maria Teresa Fonseca, Laura Maria Lasmar, Alessandra Lúcia Machado, Vera Lúcia Anastácio
Journal: European Respiratory Journal (2011)

Introduction:  Duchenne muscular dystrophy (DMD) is a genetic, progressive and disabling disease. Functionally, it puts a restrictive respiratory disorder. Faced with signs and symptoms of chronic respiratory failure should be started as ventilatory support (VS), usually in the second half of adolescence, which was initially due to nocturnal hypoventilation.  Ventilar  Program (VP) assist DMD patients VS-users and VS-non users in John Paul II Child Hospital/Hospitalar Foundation of Minas Gerais State (JPIICH/FHEMIG).   Objective:  To identify among patients with DMD assisted by the VP/JPIICH/FHEMIG, possible risk factors for the need early VS.   Patients and methods:  Cohort study between 2002-2010. Clinical score 20 points (1 point for each sign of hypoventilation). Risk factors associated with VS were evaluated in multivariate analysis by proportional hazards model of Cox. Multivariate model of Cox: all variables p   Results:  Statitically significant difference in univariate analysis for risk factors: body mass index: p=0.15, difficulty swallowing (p=0.05), moderate to severe scoliosis (p=0.01), age at loss of ambulation (p 17 points (p   Conclusion:  Age at loss of ambulation and clinical score were independent risk factors for the installation of VS before 20 years of age of DMD patients.
The spectrum of neutrophilic dermatoses associated with monoclonal gammopathy: Association with IgA isotype and inflammatory profile
Authors: Raphael Szalat, Gentiane Monsel, Wilfried Le Goff, Maxime Battistella, Djaouida Bengouffa, Marie-Helene Schlageter, Jean-David Bouaziz, Bertrand Arnulf, Marguerite Vignon, Philippe Lesnik, Anne Saussine, Marion Malphettes, Anne Lazareth, Marie-Dominique Vignon-Pennamen, Martine Bagot, Jean-Claude Brouet, Jean-Paul Fermand, Michel Rybojad, Bouchra Asli
Journal: Journal of the American Academy of Dermatology (2015)
Critically Ill Patients’ Preferences Regarding Aggressive Medical Interventions
Authors: Jamie H. Von Roenn
Journal: JAMA Oncology (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Molecular characterisation and clonal analysis of group A streptococci causing pharyngitis among paediatric patients in Palermo, Italy
Authors: G. Lorino, G. Gherardi, S. Angeletti, M. De Cesaris, N. Graziano, S. Maringhini, F. Merlino, F. Di Bernardo, G. Dicuonzo
Journal: Clinical Microbiology and Infection (2006)
Comparison of immunohistochemistry (IHC) and quantitative RT-PCR: ER, PR, and HER2 receptor status.
Authors: Cindy Christopherson, Monica Chang, David A. Eberhard, John J. Sninsky, Steven M. Anderson, Alice M. Wang, Shirley Kwok, Benjamin Calhoun
Journal: Journal of Clinical Oncology (2012)

47 Background: IHC is the present standard for measuring estrogen (ER) and progesterone receptor (PR) expression for breast cancer. However, the lack of concordance between testing laboratories and the critical patient treatment decisions made with results prompted ASCO/CAP to recommend guidelines and proficiency testing requirements to ensure accuracy. Quantitative RT-PCR (qRT-PCR) is an alternative method for ER and PR testing and while concordance with IHC has been reported, additional testing is merited. This study compares ER, PR and HER2 status determined by IHC and qRT-PCR. Methods: FFPE tissues of ER(+) tumors collected and tested at the Blumenthal Cancer Center were studied. Expression levels of ESR1, PGR, and ERBB2 were determined by a multiplex qRT-PCR TaqMan assay and by the Oncotype Dx assay. Pre-established cutpoints were used to determine positivity. Only samples with qRT-PCR and corresponding IHC data were used, resulting in 144 ER, 128 PR, and 107 HER2 comparisons. ESR1 and PGR expression levels determined by the two qRT-PCR assays were also compared. Results: Of the144 IHC ER(+) samples, 142 were positive and 2 were negative by both qRT-PCR assays. All 120 IHC PR(+) samples were positive by both qRT-PCR assays. Of the 8 IHC PR(-) samples, 5 were negative and 3 were positive by both qRT-PCR assays. Of the 107 IHC HER2(-) samples, all but 2 were negative by qRT-PCR. One sample was positive by both qRT-PCR assays; one was positive by Oncotype Dx only. The expression levels determined by the qRT-PCR assays showed good correlation for ESR1 (r=0.85) and PGR (r=0.9). Conclusions: Concordance between qRT-PCR and IHC was 98.6% for ER and 97.7% for PR. Except for a single HER2 determination, there was 100% concordance between the two qRT-PCR assays. The discordant sample was HER2 (+) by multiplex qRT-PCR and “equivocal” by Oncotype Dx. Excellent correlation was also observed in the mRNA expression levels. The absence of HER2(+) and ER(-) samples are limitations of this study. These results suggest that qRT-PCR is a promising alternative method to IHC for determining hormone receptor status. Additional testing of samples with endocrine therapy outcomes including ER(-) samples would be beneficial.
Metabolism of N-Nitrosohexamethyleneimine2
Authors: Carter J. Grandjean
Journal: JNCI Journal of the National Cancer Institute (1976)

The metabolism of [2-14C]N-nitrosohexamethyleneimine in male MRC-Wistar rats was studied and some of the major urinary metabolites were identified. The extent of total oxidation to 14CO2 was 18.1% in 24 hours and radioactivity incorporation was observed in various tissues; that in the liver was the highest. Analysis of urine after 24 hours showed that 36.7% of the radioactivity administered was excreted by this route, with a minimum of 11 products present. Hexamethyleneimine (HX), epsilon-caprolactam, epsilon-aminocaproic acid, and 6-aminocaprohydroxamic acid were the identified metabolites. Of the remaining products, two appeared to result from HX metabolism and one was a glucuronide conjugate. No parent compound was found.
Adverse Reactions in Ten Years' General Practice, Computer Analysed
Authors: R A Johnson
Journal: Journal of the Royal Society of Medicine (1986)

A total of 167 264 symptoms were recorded in numerical shorthand during a ten years period in a general practice. Computer analysis yielded 1535 adverse reactions with the drug prescribed. Especially prominent were reactions from three antibiotics (13% of all reported reactions), most of which were alimentary symptoms. Ampicillin also induced rashes reported at a rate of 5.2 per thousand prescriptions. Reactions to an oral contraceptive (Minovlar) were the most frequent to a single named drug, being 25.9% of prescriptions for that drug. A worldwide total of around one trillion symptoms seems likely before AD 2000. Computers could be used to detect the unpredictable side effects, as with practolol. Various 'costs' involved are noted, together with wider questions.
A case of dengue type 3 virus infection imported from Africa to Italy, October 2009
Authors: C Nisii, F Carletti, C Castilletti, L Bordi, S Meschi, M Selleri, R Chiappini, D Travaglini, M Antonini, S Castorina, F N Lauria, P Narciso, M Gentile, L Martini, G Di Perri, S Audagnotto, R Biselli, M Lastilla, A Di Caro, M R Capobianchi, G Ippolito
Journal: Eurosurveillance (2010)

In October 2009, a traveller returning from Africa to Italy was hospitalised with symptoms suggestive of a haemorrhagic fever of unknown origin. The patient was immediately placed in a special biocontainment unit until laboratory investigations confirmed the infection to be caused by a dengue serotype 3 virus. This case reasserts the importance of returning travellers as sentinels of unknown outbreaks occurring in other countries, and highlights how the initial symptoms of dengue fever resemble those of other haemorrhagic fevers, hence the importance of prompt isolation of patients until a final diagnosis is reached.
Patients with malignant pleural effusions who are treated with indwelling pleural catheters spend fewer days in hospital
Authors: Edward Fysh, A. William Musk, Y.C. Gary Lee
Journal: European Respiratory Journal (2011)

Introduction:  Malignant pleural effusions (MPE) are common and reducing hospitalization is a key management goal for these patients. Treatment strategies are changing with the advent of indwelling pleural catheters (IPC), a new ambulatory treatment for patients with MPE. We hypothesized that those patients managed with IPC spend fewer days in hospital than those undergoing talc pleurodesis.   Methods:  A prospective, non-randomized study involving all three major respiratory centers in Western Australia. Patients diagnosed to have MPE were prospectively followed up until death or to the end of the one year study. In the absence of accepted guidelines for IPC-use, the choice of treatments (pleurodesis, IPC or repeated thoracentesis) was made by the treating clinicians. Hospital admissions were analysed on an intention to treat basis from the time of the first procedure.   Results:  160 patients with MPE were recruited. 31 patients were managed with talc pleurodesis, and 34 received an IPC. The remaining patients only required simple thoracentesis, either because of poor prognosis, lack of effusion recurrence, or lack of symptom relief with initial drainage.  Total hospital admission days were significantly lower in patients treated with IPC (median, 25-75th percentiles) at 6.5 days (3.75-13.0) compared with pleurodesis at 18.0 days (8.0-26.0),  p= 0.002 (Mann-Whitney ranked sum test). Effusion-related admissions were even more significantly reduced at 3.0 days (1.75-8.25) against 10 (6.0-18.0), p   Conclusion:  Patients with MPE who are treated with an IPC spend fewer days in hospital compared with pleurodesis.
Factors Contributing to Post–Lumbar Puncture Headache
Authors: Samad E. J. Golzari, Ata Mahmoodpoor, Reza Rikhtegar
Journal: JAMA Neurology (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Association between GWAS-Derived rs966423 Genetic Variant and Overall Mortality in Patients with Differentiated Thyroid Cancer
Authors: Michał Świerniak, Anna Wójcicka, Małgorzata Czetwertyńska, Joanna Długosińska, Elżbieta Stachlewska, Wojciech Gierlikowski, Adam Kot, Barbara Górnicka, Łukasz Koperski, Magdalena Bogdańska, Wiesław Wiechno, Krystian Jażdżewski
Journal: Clinical Cancer Research (2015)

Five germline genetic variants (rs116909374, rs965513, rs944289, rs966423, and rs2439302) have been associated in genome-wide association studies (GWAS) with increased risk of differentiated thyroid cancer (DTC), but their role in mortality of patients has not been established. Also, no preoperative marker of the clinical outcome of thyroid cancer had yet been identified. The aim of the study was to investigate the relationship between the variants and overall mortality in patients with DTC.Retrospective study of 1,836 patients (1,643 women, 193 men) with median age at diagnosis of 49 years and overall median follow-up time of 8.7 years after initial treatment at a single comprehensive cancer center between 1990 and 2013.Among 5 variants, rs966423 was associated with increased mortality, which was 6.4% (33 of 518) versus 3.7% (47 of 1,259) in TT carriers versus CC/CT carriers (P = 0.017). The HR of TT versus TC/CC carriers was 1.6 [95% confidence interval (CI), 1.02-2.49; P = 0.038] after adjustment for age at diagnosis and sex. Importantly, the association of rs966423 with mortality remained valid when clinicopathologic risk factors were included in the model (HR, 1.89; 95% CI, 1.14-3.13; P = 0.014). Higher rs966423-associated patient mortality of TT versus CC/CT carriers was also observed in interaction with angioinvasion (adjusted HR, 3.48; 95% CI, 1.67-7.22; P < 0.001), lymph node metastasis (adjusted HR, 3.47; 95% CI, 1.16-10.4; P = 0.018), extrathyroidal invasion (adjusted HR, 2.07; 95% CI, 1.15-3.73; P = 0.013).The presence of the rs966423-TT genotype was associated with a significant increase in overall mortality of patients with DTC. Contrary to BRAF mutation and other somatic changes, the status of germline rs966423 is known before the treatment and might be used in the management of mortality risk by means of modification of therapy.